Phenobarbital hepatotoxicity in an 8-month-old infant.
Severe hepatotoxicity from phenobarbital occurred in an infant boy who had a complicated illness with chronic bilateral subdural hematomas and sepsis. Skin rash began after 2 weeks of treatment, and signs of hepatocellular failure developed 3 weeks after phenobarbital had been started. Signs of severe liver disease included elevated aminotransferases, conjugated hyperbilirubinemia, significant coagulopathy, hepatosplenomegaly and ascites. Other features of this adverse drug reaction were unremitting fever, leukocytosis with eosinophilia and atypical lymphocytosis, and proteinuria. Sepsis, viral hepatitis, and metabolic liver disease were excluded. The child was on no other medication and had been previously well. In-vitro rechallenge of the patient's lymphocytes with cytochrome P-450 generated metabolites of phenobarbital showed extensive cytotoxicity compared to control. These data support the hypothesis that a defect in drug detoxification was responsible for the child's susceptibility to this drug hepatotoxicity.
Roberts
E A
EA
Department of Paediatrics, Hospital for Sick Children, Toronto, Ontario, Canada.
Spielberg
S P
SP
Goldbach
M
M
Phillips
M J
MJ
D002220:Carbamazepine / Q000009:adverse effects; D002470:Cell Survival / Q000187:drug effects; D056486:Chemical and Drug Induced Liver Injury / Q000188:drug therapy / Q000209:etiology*; D006801:Humans; D007223:Infant; D008214:Lymphocytes / Q000187:drug effects; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D010634:Phenobarbital / Q000009:adverse effects*; D010672:Phenytoin / Q000009:adverse effects
D002220:Carbamazepine; D010672:Phenytoin; D008775:Methylprednisolone; D010634:Phenobarbital